노인환자에서 위장관계 및 심혈관계 부작용 발생 예방을 위한 NSAIDs 사용의 적절성 평가
Evaluation of Proper Use of NSAIDs to Prevent Gastrointestinal and Cardiovascular Problems in Elderly Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Elderly patients with gastrointestinal (GI) and cardiovascular (CV) risk factors may be more easilyexposed to NSAID-related side effects (SEs). Based on the ACG guideline of year 2009, the aim of the study is toevaluate proper use of NSAIDs and gastroprotective drugs according to the degree of GI and CV risk strengths in thepatients. Methods: Retrospectively surveyed 410 elderly patients with NSAIDs for more than 30 days at a general hospitalin Korea. GI risk factor includes age, ulcer history, high-dose NSIADs, concurrent aspirin use, steroids or anticoagulants. CV risk factor includes angina, myocardial infarction, cerebral infarction, atrial fibrillation or coronaryintervention requiring low-dose aspirin. These factors were classified as high/low cardiovascular groups and high/moderate/low GI groups. Results: There were 14 patients in high CV risk group and high GI risk group. The group was recommendednot to use NSAIDs as it is not adequate. There were 101 patients in high CV risk group and moderate GIrisk group. This group was recommended to use naproxen and PPI/misoprostol. But all patients except one were notadequate. There were 9 patients in low CV risk group and high GI risk group. This group was recommended to useselective COX-2 inhibitor and PPI/misoprostol. 5 cases were proper while 4 cases did not. There were 285 patients inlow CV risk and moderate GI risk group who were recommended to use non selective NSAIDs and PPI/misoprostol orselective COX-2 inhibitor only. 103 patients were proper while 182 patients not adequate. Overall, the SEs were higherin those cases for inadequate use of drugs comparing to the adequate. CV SEs were statistically significant. However,SEs for each risk groups were different. For the case of low CV risk group and high/moderate GI risk group, the inadequateuse of drugs makes the SE high and the other groups are not. Also, it was not statistically significant. Conclusions:In elderly patients, the inappropriate use of NSAIDs can increase the risk of the disease. Therefore, GI and CVrisk must be considered simultaneously, and the proper use of NSAIDs and gastroprotective drugs for each risk groupsshould be reconsidered.
Abstract
Background: Elderly patients with gastrointestinal (GI) and cardiovascular (CV) risk factors may be more easilyexposed to NSAID-related side effects (SEs). Based on the ACG guideline of year 2009, the aim of the study is toevaluate proper use of NSAIDs and gastroprotective drugs according to the degree of GI and CV risk strengths in thepatients. Methods: Retrospectively surveyed 410 elderly patients with NSAIDs for more than 30 days at a general hospitalin Korea. GI risk factor includes age, ulcer history, high-dose NSIADs, concurrent aspirin use, steroids or anticoagulants. CV risk factor includes angina, myocardial infarction, cerebral infarction, atrial fibrillation or coronaryintervention requiring low-dose aspirin. These factors were classified as high/low cardiovascular groups and high/moderate/low GI groups. Results: There were 14 patients in high CV risk group and high GI risk group. The group was recommendednot to use NSAIDs as it is not adequate. There were 101 patients in high CV risk group and moderate GIrisk group. This group was recommended to use naproxen and PPI/misoprostol. But all patients except one were notadequate. There were 9 patients in low CV risk group and high GI risk group. This group was recommended to useselective COX-2 inhibitor and PPI/misoprostol. 5 cases were proper while 4 cases did not. There were 285 patients inlow CV risk and moderate GI risk group who were recommended to use non selective NSAIDs and PPI/misoprostol orselective COX-2 inhibitor only. 103 patients were proper while 182 patients not adequate. Overall, the SEs were higherin those cases for inadequate use of drugs comparing to the adequate. CV SEs were statistically significant. However,SEs for each risk groups were different. For the case of low CV risk group and high/moderate GI risk group, the inadequateuse of drugs makes the SE high and the other groups are not. Also, it was not statistically significant. Conclusions:In elderly patients, the inappropriate use of NSAIDs can increase the risk of the disease. Therefore, GI and CVrisk must be considered simultaneously, and the proper use of NSAIDs and gastroprotective drugs for each risk groupsshould be reconsidered.
참고문헌 (38)
- Laine L., "Approaches to Nonsteroidal Anti-inflammatory Drug Use in the High-Risk Patient", Gastroenterology, 120, pp.594~606 (2001)
- Kim DS., "The dupication of NSAIDs and management plan", HIRA Policy Trend, 7(4), pp.7~8 (2013)
- Barat I., "The consumption of drugs by 75-year old individual living in their own homes", Eur J Cln Pharmcol, 56, pp.501~509 (2000)
- Larkai EN., "Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic NSAIDs use", Am J Gastroenterol, 82, pp.1153~1158 (1987)
- Laine L., "Nonsteroidal anti-inflammatory drug gastropathy", Gastrointest Endosc Clin North Am, 6, pp.489~504 (1996)
- Silverstein FE., "Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis : the CLASS study : A randomized controlled trial. Celecoxib Long-term Arthritis Safety study", JAMA, 284, pp.1247~1255 (2000)
- Bombardier C., "Comparison of upper gastrointestinal toxicity of rofecoixb and naproxen in patients with rheumatoid arthritis. VIGOR study group", N Engl J Med, 343, pp.1520~1528 (2000)
- Hawkey CJ., "Nonsteroidal anti-inflammatory drug gastropathy", Gastroenterology, 119, pp.521~535 (2000)
- Ray WA., "COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease", Lancet, 360, pp.1071~1073 (2002)
- Kearney PM., "Do selective COX-2 inhibitors and nonselective NSAIDs increase the risk of atherothrombosis, Meta-anaylsis of randomised trials", BMJ, 332, pp.1302~1308 (2006)
- McGettign P., "Cardiovascular risk and inhibition of cycooxygenase : A systematic review of the observational studies of selective and nonselective inhibitors of cycloocygenase 2", JAMA, 296, pp.1633~1644 (2006)
- Abraham NS., "Cyclooxygenase-2 selectivity of NSAIDs and the risk of myocardial infarction and cerebrovascular accident", Aliment Pharmacol Ther, 25, pp.913~924 (2007)
- Antman EM., "Use of nonsteroidal antiinflammatory drugs : An update for clinicians : A scientific statement from the American Heart Association", Circulation, 115(12), pp.1634~1642 (2007)
- "NICE (National Institute for Health and Clinical Excellence)"[URL]
- Francis KL., "James M. Management of Patients on NSAID : A Clinical Practice Recommendation From the First International Working Party on Gastrointestinal and Cardiovascular Effects of NSAIDs and Antiplatelets agents", Am J Gastroenterol, 103, pp.2908~2918 (2008)
- Frank L., "Guidelines for Prevention of NSAID-Related Ulcer Complications", Am J Gastroenterol, 104, pp.728~738 (2009)
- James M., "Strategies to optimize Treatment with NSAIDs in Patients at Risk for Gastrointestinal and Cardiovascular Adverse Event", Clin Ther, 32, pp.667~677 (2010)
- 이준행, "비스테로이드소염제 관련 소화성궤양의 예방과 치료 가이드라인", 대한소화기학회지, 54(5), pp.309~317 (2009), 대한소화기학회
- Breninan MR., "Minimizing Complications From Nonsteroidal Antiinflammatory Drugs : Cost-Effectiveness of Competing Strategies in Varying Risk Groups", Arthritis & Rheumatism, 53(2), pp.185~197 (2005)
- Laura E., "Peter A. Gastroprotective strategies among NSAID users", Can Fam Physician, 52, pp.1100~1105 (2006)
- James KK., "Gastroprotection in trauma patiets receiving non-steroidal anti-inflammatory drugs", The surgeon, 8, pp.206~210 (2010)
- Kristina J., "Concomitant Use of Gastroprotective Drugs among Elderly NSAID", COX-2 Selective Ihnibitor Users, 2008, pp.11, 687~695
- 조정원, "비스테로이드소염제로 인한 궤양 합병증 예방을 위한 비스테로이드소염제 사용 현황 및 적절성 평가", 한국임상약학회지, 22(3), pp.211~219 (2012), 한국임상약학회
- "Guidelines for Use of NSAIDs and COX-2 selective agents; the ASHP"[URL]
- Hawkey CJ., "Omeprazle compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs", N Engl J Med, 338, pp.727~734 (1998)
- Rose P., "Evidence that lansoprazole is effective in preventing NSAID induced ulcers", Gastroenterology, 116, pp.A295~ (1999)
- Silverstein FE., "Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal antiinflammatory drugs. A randomized, double-blind, placebocontrolled trial", Ann Intern Med, 123, pp.241~249 (1995)
- Graham DY., "Duodenal and gastric ulcer prevention with misoprostol in arthritic patients taking NSAIDs", Ann Inter Med, 119, pp.257~262 (1993)
- Raskin JB., "Misoprostol dosage in the prevention of nonsteroidal anti-infammatory drug-induced gastric and duodenal ulcers : a comparison of three regimens", Ann Intern Med, 123, pp.344~350 (1995)
- Taha AS., "Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs", N Engl J Med, 334, pp.1435~1439 (1996)
- Elsa Lopez-Pintor., "Use of gastrointestinal prophylaxis in NSAID patients : a cross sectional study in community pharmacies", Int J Clin Pharm, 33, pp.155~164 (2011)
- Trelle S., "Cardiovascular safety of non-steroidal anti-inflammatory drugs : network meta-analysis", BMJ, 342, pp.c7086~ (2011)
- Francesca CL., "Cyclooxygenase inhibitors and the antiplatelet effects of aspirin", N Engl J Med, 345, pp.1809~1817 (2001)
- Renda G., "Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease", Clin Pharmaco Ther, 80, pp.264~274 (2006)
- Capone ML., "Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects", J Am Coll Cardiol, 45, pp.1295~1301 (2005)
- LEE GY., "How to Use NSAID in Patients with Cardiovascular Disease", J Orthop Pain Society, 2, pp.40~43 (2012)
- Patrignani P., "Managing the adverse effects of nonsteroidal anti-inflammatory drugs", Expert Rev Clin Pharmacol, 4, pp.605~621 (2011)
- Graham DY., "NSAIDs, risk, and gastropretective strategies : current status and futures", Gastroenterology, 134, pp.1240~1246 (2008)